A recent study [31] demonstrated that CD155 expression in tumor cells was associated with resistance to anti-PD-1 immunotherapy in patients with metastatic malignant melanoma, and it has been speculated that blockade of CD155 may improve the response to anti-PD-1 therapy. The gene discussed is PDCD1; the disease is metastatic melanoma.